Viking Global Investors
VKTX icon

Viking Global Investors’s Viking Therapeutics VKTX Stock Holding History

Viking Global Investors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-721,926
Closed -$45.7M – 101
2024
Q3 		$45.7M Sell
721,926
-632,524
-47% -$37.1M 0.17% 74
2024
Q2 		$71.8M Buy
1,354,450
+259,510
+24% +$17M 0.28% 62
2024
Q1 		$89.8M Sell
1,094,940
-4,050,172
-79% -$180M 0.33% 57
2023
Q4 		$95.8M Buy
5,145,112
+571,796
+13% +$7.48M 0.35% 58
2023
Q3 		$50.6M Buy
4,573,316
+1,028,810
+29% +$14.7M 0.21% 66
2023
Q2 		$57.5M Buy
3,544,506
+1,589,443
+81% +$33.3M 0.24% 71
2023
Q1 		$32.6M Buy
+1,955,063
New +$20.2M 0.15% 70

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors's VKTX Position: Q4 2024 in Review

Viking Global Investors sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 721,926 shares — an estimated $45.7M sold.

Viking Global Investors first reported a position in VKTX in Q1 2023 and held it in 7 quarters. The position peaked at $95.8M in Q4 2023. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • Viking Global Investors reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Viking Global Investors sold 721,926 Viking Therapeutics shares in Q4 2024, an estimated $45.7M.
  • Viking Global Investors first reported a position in Viking Therapeutics in Q1 2023 and held it in 7 quarters.
  • Viking Global Investors's Viking Therapeutics position peaked at $95.8M in Q4 2023.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Viking Global Investors's 13F filing for Q4 2024, filed 14 Feb 2025.